Prolight Diagnostics AB
NNGM:PRLD17.80
SEK
-0.18
(-1.00%)
ISIN
SE0027099656
Return %
Stock
S&P 500
1Y
1.71
14.20
3Y
-71.90
81.12
5Y
-86.11
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Ulf Bladin
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Lund Sweden
- IPO Date
- Mar 31, 2017
- Website
- prolightdx.com
- Similar Companies
- Business
- Prolight Diagnostics AB (publ) (PRLD.ST) develops innovative point-of-care (POC) diagnostic systems for in-vitro (IVD) testing from a drop of blood, utilizing small portable instruments and disposable cartridges to enable rapid testing outside traditional hospital laboratories in settings such as emergency departments, ambulances, healthcare centers, and nursing homes. The company's core offerings include the Psyros TM digital immunoassay platform, which employs proprietary single-molecule counting technology to measure biomarkers at ultra-low concentrations (single-digit ng/L) in approximately 10 minutes with laboratory-grade precision and multiplex capability; and the MicroFlex POC system, which integrates micro-ELISA with Flex Membrane technology for distributed diagnostic testing equivalent to central lab performance, including innovations like the eco-friendly ecoflex cartridge. These systems target acute cardiac conditions, starting with high-sensitivity troponin assays for rule-in/rule-out of myocardial infarction, with potential expansion to other biomarkers such as BNP/Nt-proBNP and D-Dimer across diverse clinical areas. Founded in 1999 and headquartered in Lund, Sweden, with a UK subsidiary Psyros Diagnostics Ltd. in Sandwich, Kent, the company operates primarily in Europe and employs approximately 16-21 staff. In recent developments, Prolight acquired UK-based Psyros Diagnostics in early 2022 to incorporate its cutting-edge digital POC technology, enhancing capabilities for troponin and TSH measurement demonstrated in proof-of-performance studies in 2022-2023; signed a commercialization agreement in November 2022 with The Technology Partnership plc (TTP) for further MicroFlex development and partner sourcing; received a second European Patent Office Notice of Intention to Grant in 2024 for Psyros technology extensions; announced a SEK 100 million rights issue in 2025 to fund Psyros commercialization, pre-clinical validation on whole blood (results expected Q2 2025), instrument finalization, and system verification ahead of European launch in 2026; and continues active business development with strong partner interest amid industry M&A activity, such as Roche's 2024 acquisition of LumiraDx POC technology.